A first-in-class medication, Journavx targets pain-signaling pathways involving sodium channels.
A first-in-class medication, Journavx targets pain-signaling pathways involving sodium channels.
Victoza® (liraglutide) injections are a GLP-1 receptor agonist, a drug class experiencing shortages due to their high demand.
These drugs treat opioid withdrawal and opioid-induced constipation, respectively.
This drug has been approved for the treatment of multiple chronic inflammatory disorders.
Tirzepatide was no longer considered in shortage, removing compounding privileges, until litigation remanded the decision.
The FDA issued notices for certain migraine, acetaminophen, clonazepam, and semaglutide products.
A new naloxone nasal spray will soon be available.
Patients taking this muscle relaxant may be impacted by a lot from Eugia US/AuroMedics Pharma.
As firefighters see more presumptions for heart disease, keeping track of heart medications could grow in importance.
